The manufacturers say that both
amprenavir and
erythromycin levels may be increased on concurrent use.
Fosamprenavir is predicted to interact similarly.
Monitor the outcome carefully. Advise patients to be alert for
erythromycin and
amprenavir or
fosamprenavir adverse effects (e.g.
gastrointestinal effects, tremors).